The definitive clinician’s guide to the Omega-3 Index — from its origins in a landmark 2004 paper to the clinical evidence that makes it one of the most validated nutritional biomarkers in medicine today.
The Omega-3 Index is the percentage of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in red blood cell membrane fatty acids, expressed as a proportion of total fatty acids. It reflects your average omega-3 intake over the preceding 90–120 days — the lifespan of a red blood cell.
EPA + DHA as a percentage of total red blood cell (RBC) membrane fatty acids. A value of 8% means that 8 out of every 100 fatty acids in your red blood cell membranes are EPA or DHA.
Unlike plasma or serum levels that fluctuate with meals, RBC membranes reflect long-term dietary intake over 90–120 days — analogous to HbA1c for blood glucose. This makes the Omega-3 Index a stable, clinically meaningful biomarker.
The Omega-3 Index is modifiable through diet and supplementation, and responds predictably to changes in EPA/DHA intake. This makes it actionable — clinicians can measure, intervene, and re-measure to confirm improvement.
The Omega-3 Index was proposed by two researchers who recognised that existing measures of omega-3 status were inadequate for clinical risk assessment.
Prof. Dr. med. Clemens von Schacky, a German preventive cardiologist, and Dr William S. Harris, an American nutritional biochemist, co-developed the Omega-3 Index. Von Schacky has worked scientifically on omega-3 fatty acids since 1983 and served as Head of Preventive Cardiology at Ludwig-Maximilians-Universität (LMU) Munich from 1987 to 2020, authoring more than 163 publications indexed in Medline.2
Harris completed his PhD in Nutrition and Food Science at the University of Minnesota (1978) and held positions at the University of Missouri–Kansas City and the University of South Dakota Sanford School of Medicine. Together, their complementary expertise in clinical cardiology and nutritional biochemistry laid the groundwork for a new generation of fatty acid biomarkers.
In 2004, Harris and von Schacky published “The Omega-3 Index: a new risk factor for death from coronary heart disease?” in Preventive Medicine (vol. 39, pp. 212–220).1 This paper formally proposed the Omega-3 Index as a novel risk factor for fatal coronary heart disease and established the target range of 8–11%.
The paper has since been cited over a thousand times and launched a research programme that now spans more than 440 published studies using the Omega-3 Index as a biomarker.
Von Schacky founded Omegametrix GmbH, an international reference laboratory for the HS-Omega-3 Index, based at the Innovation and Startup Center for Biotechnology (IZB) in Martinsried/Munich. Omegametrix developed and validated the standardised HS-Omega-3 Index methodology, enabling laboratories worldwide to measure the biomarker with high precision and reproducibility.2,3
Today, the HS-Omega-3 Index methodology underpins more than 440 publications in international peer-reviewed journals and has been adopted as the reference standard for omega-3 status assessment in clinical research globally.3
The Omega-3 Index is mapped to three well-established risk zones based on cardiovascular outcomes data from prospective cohort studies.1,2
Associated with significantly elevated risk of fatal coronary heart disease, sudden cardiac death, and adverse cardiovascular events. Individuals in this zone have approximately twice the risk of cardiac death compared to those above 8%. Immediate dietary intervention or supplementation is warranted.
Below the optimal range but above the highest-risk threshold. Most individuals in Western populations fall within this zone. There is a clear, dose-dependent benefit to increasing EPA+DHA intake toward the target. The Physicians’ Health Study demonstrated progressive risk reduction across this range.
The target zone. Associated with the lowest risk of fatal cardiac events and lower all-cause mortality. This range is typical of populations with high fish intake, such as Japan and South Korea, where cardiovascular mortality rates are substantially lower. Benefits plateau around 11–12%.
While the Omega-3 Index was originally developed as a cardiovascular biomarker, the research has expanded dramatically. Higher omega-3 status is now associated with favourable outcomes across a remarkably broad range of health conditions.
The most extensively studied domain. Meta-analyses of prospective cohort studies demonstrate that individuals with an Omega-3 Index below 4% have approximately twice the risk of fatal coronary heart disease compared to those above 8%.1 The biomarker is independently predictive of sudden cardiac death, myocardial infarction, and overall cardiovascular mortality.
The Omega-3 Index is now recognised alongside cholesterol, blood pressure, and HbA1c as a modifiable cardiovascular risk factor.2 It is negatively associated with inflammatory markers including C-reactive protein (CRP) and interleukin-6 (IL-6).
Higher Omega-3 Index values are associated with greater brain volume, particularly in the hippocampus, and with slower rates of cognitive decline in ageing populations. DHA is a major structural component of brain tissue, comprising approximately 40% of the polyunsaturated fatty acids in the brain.
Emerging evidence links low omega-3 status to increased risk of dementia and Alzheimer’s disease. Research suggests an Omega-3 Index risk threshold of approximately 4–5% for dementia, with blood omega-3 inversely related to risk of early-onset dementia.
DHA is critical for foetal brain and retinal development. Maternal Omega-3 Index values below 5% are associated with increased risk of preterm birth and suboptimal neurodevelopmental outcomes.6 Insufficient omega-3 during pregnancy can disrupt key neurodevelopmental processes, particularly microglial function.
Testing maternal omega-3 status allows targeted supplementation to ensure adequate DHA transfer during pregnancy — a more precise approach than blanket supplementation recommendations.
A narrative review examining 36 studies found significant differences in Omega-3 Index between patients with psychiatric conditions and healthy controls in 30 of those studies.5 The published evidence supports the Omega-3 Index as a risk factor for major depression, postpartum depression, psychosis, and dementia.
Proposed risk thresholds include approximately 4–5% for major depression and dementia, 5% for postpartum depression,6 and 4% for psychosis transition.5 EPA and DHA deficiencies are closely linked to impaired synaptic signalling and mood dysregulation.
EPA and DHA are precursors to specialised pro-resolving mediators (SPMs) — molecules that actively resolve inflammation rather than simply suppressing it. A higher Omega-3 Index reflects greater capacity for inflammation resolution.
This is clinically relevant to conditions including rheumatoid arthritis, inflammatory bowel disease, asthma, and metabolic syndrome. Pro-inflammatory conditions may be favourably influenced by improving omega-3 status.
Endurance athletes given EPA-rich and DHA-rich omega-3 supplements for six weeks showed a significant increase in their Omega-3 Index along with reductions in submaximal exercise heart rate and perceived exertion compared with placebo — suggesting improved cardiovascular efficiency in trained individuals.
Additional research links higher omega-3 status to reduced exercise-induced inflammation, faster recovery, and potential neuroprotective benefits in contact sports.
EPA and DHA are long-chain omega-3 fatty acids found primarily in marine sources. The body can convert ALA (alpha-linolenic acid) from plant sources, but conversion efficiency is very low (<5%), making direct dietary intake essential.
| Source | EPA + DHA per 100 g | Notes |
|---|---|---|
| Mackerel (Atlantic) | ~2,600 mg | One of the richest natural sources; widely available |
| Salmon (wild, Atlantic) | ~2,200 mg | Excellent source; farmed salmon also high but variable |
| Sardines (canned) | ~1,400 mg | Affordable, shelf-stable; bones provide calcium |
| Herring | ~1,700 mg | High EPA+DHA; common in Northern European diets |
| Anchovies | ~1,500 mg | Often used as fish oil supplement source |
| Trout (rainbow, farmed) | ~1,000 mg | Good freshwater source |
| Oysters | ~600 mg | Also rich in zinc and vitamin B12 |
| Tuna (canned, light) | ~300 mg | Lower than fatty fish; mercury considerations for frequent consumption |
Standard fish oil capsules (1,000 mg) typically provide 300 mg EPA+DHA combined. Concentrated formulations provide 600–900 mg per capsule. Prescription omega-3 products (e.g., icosapent ethyl) provide even higher doses for clinical indications.
Microalgae-derived DHA (and increasingly EPA) supplements offer a plant-based alternative. These are the original source of omega-3 in the marine food chain — fish accumulate EPA/DHA by eating algae or organisms that eat algae.
Plant-based ALA from flaxseed, chia, and walnuts is an essential omega-3 but converts to EPA/DHA at less than 5% efficiency. ALA-rich diets alone are unlikely to raise the Omega-3 Index to the target range without supplemental EPA/DHA.
The Omega-3 Index is modifiable. Clinical experience and published data provide clear guidance on how to move patients from the risk zone into the target range.
Test the Omega-3 Index before recommending supplementation. A baseline value allows you to set a target, choose an appropriate dose, and measure response objectively — moving from guesswork to evidence-based dosing.
Two or more servings of fatty fish per week (salmon, mackerel, sardines, herring) provide approximately 500 mg EPA+DHA daily. This is sufficient to move many patients into the 6–8% range but may not reach the >8% target without supplementation.
For most patients starting below 4%, 1,000–2,000 mg of EPA+DHA daily (not total fish oil) is typically needed to reach the target range within 4–6 months. Response varies with baseline status, body weight, genetics, and competing dietary fats.
Because the Omega-3 Index reflects 90–120 days of intake, allow at least 4 months before re-testing. This confirms whether the intervention achieved the target, and allows dose adjustment if needed. Longitudinal tracking builds an objective record of patient compliance and response.
The Omega-3 Index is one of the most extensively studied nutritional biomarkers in clinical medicine, with a growing body of evidence supporting its use across multiple health domains.
Founded by Prof. von Schacky, Omegametrix GmbH is the international reference laboratory for the HS-Omega-3 Index, based at the Innovation and Startup Center for Biotechnology (IZB) in Martinsried/Munich. Omegametrix provides quality-assured fatty acid analytics for clinical trials and research programmes worldwide.2
The HS-Omega-3 Index is a standardised, validated methodology for measuring EPA+DHA in RBC membranes using gas chromatography. Developed and maintained by Omegametrix, it enables consistent, reproducible results across laboratories and makes study findings directly comparable — forming the analytical backbone of more than 440 published studies.3
Recent studies continue to confirm the utility of the Omega-3 Index across new domains — from athletic performance and recovery to age-related macular degeneration, pregnancy outcomes, and psychiatric conditions. A 2016 global survey mapped blood EPA+DHA levels across populations worldwide, revealing widespread deficiency.4
Partner with Fatty Acid Labs for validated, scalable Omega-3 Index testing using the same GC-FID methodology trusted in clinical research worldwide.